Global engineered T cells market is projected to reach $2,124
million by 2023, growing at a CAGR of 46.5% from 2017 to 2023.
Engineered T cells are also known as specifically modified T
cells, which are designed for the treatment of autoimmune diseases, primary
immune deficiencies, and cancer. Upon delivery, engineered T cells enable
reduction of toxicities and inhibit antigen escape (inability of immune system
to respond to an infectious agent). The engineered T cells assist immune system
to overcome the immunosuppressive tumor microenvironments and target cancer
cells for effective treatment.
Download PDF
Report Sample @ https://www.alliedmarketresearch.com/request-sample/4538
The major players profiled operating in the global engineered T
cells market are
·
Autolus Limited
·
Bellicum PharmaceuticalsInc.
·
Cells Medica
·
Elli Lilly and Company
·
Gilead SciencesInc.
·
Juno Therapeutics
·
Novartis AG
·
Oxford Biomedica
·
Pfizer Inc.
·
Precision Bioscience
Increase in global prevalence of cancer and surge in demand for
innovative biopharmaceutical therapies is projected to drive the growth of the
engineered T cells market. In addition, advantages offered by engineered T
cells therapies such as targeted action and less side effects are expected to
boost the demand for engineered T cells in future.
Chimeric antigen receptor (CAR) modified T cells segment is
projected to dominate the market during the analysis period, due to surge in
utilization of chimeric antigen receptor T cells in research facilities.
By application, lung cancer garnered the highest market share in
2016, and expected to dominate during the analysis period, owing to increase in
incidence of lung cancer and high utilization of engineered T cells for the
treatment of lung cancer.
Hospitals have the extensive use of engineered T cells, hence,
it held the highest market value in 2016, and is expected to lead the market
during the analysis period.
For More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/4538
Key Findings of the Engineered T-cells Market:
- Chimeric antigen receptor modified T
Cells segment accounted for more than half of the global market share in
2016.
- T cells receptor (TCR) segment is
expected to grow at a highest CAGR.
- Asia-Pacific is anticipated to grow at
the highest rate during the analysis period, followed by Europe.
- China and India are the major market
shareholders in Asia-Pacific.
Geographically, North America dominated the market, accounting
for approximately half of the overall market in 2016. This can be attributed to
various factors such as presence of leading biotech companies and modern
research facilities in the region. Furthermore, Asia-Pacific is projected to
register the highest growth due to surge in number of biopharmaceutical
companies and increase in acceptance of modern cancer treatments.
Access Full Summery @ https://www.alliedmarketresearch.com/press-release/engineered-T-cells-market.html
No comments:
Post a Comment